The Corticosteroid 11 Beta Dehydrogenase Isozyme 1 pipeline drugs market research report outlays comprehensive information on the Corticosteroid 11 Beta Dehydrogenase Isozyme 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Corticosteroid 11 Beta Dehydrogenase Isozyme 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Metabolic Disorders, Ophthalmology, Central Nervous System, and Immunology which include the indications Type 2 Diabetes, Diabetic Complications, Glaucoma, Diabetic Retinopathy, Alzheimer’s Disease, Dementia Associated With Alzheimer’s Disease, and Inflammation. It also reviews key players involved in Corticosteroid 11 Beta Dehydrogenase Isozyme 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Corticosteroid 11 Beta Dehydrogenase Isozyme 1 pipeline targets constitutes close to 12 molecules. Out of which, approximately eight molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 4, 1, 2, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 4 molecule.
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 overview
11beta-hydroxysteroid dehydrogenase type 1 is an NADPH-dependent enzyme highly expressed in key metabolic tissues including liver, adipose tissue, and the central nervous system. In these tissues HSD11B1 reduces cortisone to the active hormone cortisol that activates glucocorticoid receptors. This enzyme plays an important role in obesity and insulin resistance.
For a complete picture of Corticosteroid 11 Beta Dehydrogenase Isozyme 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
